Literature DB >> 31858715

Predictive factors for work-day loss in Behçet's syndrome: A multi-center study.

Gonca Mumcu1, Meral Yay2, Aysun Aksoy3, Mehmet Nedim Taş4, Berkan Armağan5, Alper Sarı5, Burçin Cansu Bozca6, Emre Tekgöz7, Duygu Temiz Karadağ8, Suade Özlem Badak9, Duygu Tecer10, Cemal Bes11, Ali Şahin12, Eren Erken9, Ayse Cefle8, Muhammet Çınar7, Sedat Yılmaz7, Ümit Karaçaylı13, Erkan Alpsoy6, Soner Şenel14, Şule Yaşar Bilge15, Timuçin Kaşifoğlu15, Ömer Karadağ5, Kenan Aksu4, Gökhan Keser4, Fatma Alibaz-Öner3, Nevsun İnanç3, Tülin Ergun16, Haner Direskeneli3.   

Abstract

OBJECTIVE: The aim of this multi-center study was to assess predictive factors for work-day loss as an indirect cost element in Behçet's syndrome (BS).
METHODS: In this cross-sectional, multi-center study, 834 BS patients (F/M: 441/393, age mean: 38.4 ± 10.9 years) were included. Data were collected by a questionnaire regarding treatment protocols, disease duration, smoking pattern, frequency of medical visits during the previous year and self-reported work-day loss during the previous year.
RESULTS: Work-day loss was observed in 16.2% of patients (M/F: 103/32). The percentages of being a smoker (81.8%), using immunosuppressive (IS) medications (82%), and having disease duration <5 years (74%) were higher in male patients with work-day loss (P < .05). The majority of males (90.9%) had more than four clinic visits during the previous year. Moreover, the mean work-day loss (30.8 ± 57.7 days) was higher in patients with vascular involvement (56.1 ± 85.9) than those without (26.4 ± 50.6 days) (P = .046). In addition, increased frequency of ocular involvement (25.9%) was also observed in patients with work-day loss compared to others (8.6%) (P = .059).
CONCLUSION: Work-day loss was associated with both vascular and ocular involvement. Close associations were observed among male gender, early period of the disease, frequent medical visits, being a smoker and treatment with IS medications in patients with work-day loss.
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Behçet's disease; ocular involvement; vascular involvement; work-day loss

Year:  2019        PMID: 31858715     DOI: 10.1111/1756-185X.13771

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  2 in total

Review 1.  Behçet Disease: An Update for Dermatologists.

Authors:  Erkan Alpsoy; Burcin Cansu Bozca; Asli Bilgic
Journal:  Am J Clin Dermatol       Date:  2021-06-01       Impact factor: 7.403

Review 2.  Experimental Therapeutic Solutions for Behcet's Disease.

Authors:  Burçin Cansu Bozca; Erkan Alpsoy
Journal:  J Exp Pharmacol       Date:  2021-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.